Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

Recruiting now

Conditions studied: Autoimmune Lymphoproliferative Syndrome, Autoimmune Cytopenia, Autoimmune Diseases, Autoimmune Anemia, Autoimmune Thrombocytopenia, Autoimmune Hepatitis, Autoimmune Diabetes, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus, Juvenile Idiopathic Arthritis, Hemophagocytic Lymphohistiocytoses, EBV Lymphoproliferation, RAS-Associated Autoimmune Leucoproliferative Disease, Primary Immunodeficiency, APECED, IPEX, BENTA, Enteropathy, Autoimmune, Combined Immunodeficiency, IBD

In brief

The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).

Key facts

Study ID

NCT04902807

Run by

Institut National de la Santé Et de la Recherche Médicale, France

People needed

500

Starts

2021-09-07

Expected to finish

2026-06-01

Last updated by the study team

2025-09-08

Who can join

Age: 1 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Intake of antibiotics within 2 weeks prior inclusion
• Absence of parent's or child consent form
• Cytotoxic cancer treatments
• antiviral treatments (HIV, hepatitis …)
• Short term life-threatening conditions
• Individuals placed under judicial protection

Where it is running

• hôpital Necker Enfants Malades — Paris, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.